Revolution Medicines Announces Publication In Cancer Discovery Demonstrating Robust Anti-Tumor Activity Of RAS(ON) Inhibitors In Preclinical Models Of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Revolution Medicines Announces Publication In Cancer Discovery Demonstrating Robust Anti-Tumor Activity Of RAS(ON) Inhibitors In Preclinical Models Of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC)
发表在《癌症发现》上的原始研究表明，在难以治疗的KRAS突变非小细胞肺癌（NSCLC）的临床前模型中，一种RAS（ON）多选择性抑制剂单独或与RAS（ON）G12C选择性抑制剂联合使用表现出强大的抗肿瘤活性
Results also highlight that, in contrast to mutant-selective RAS inhibition, broad-spectrum, reversible RAS-GTP inhibition with a RAS(ON) multi-selective inhibitor alone drove durable anti-tumor activity in these models with infrequent resistance occurrence and the potential for emergence of rare persister, slow cycling cells
结果还突出表明，与突变体选择性RAS抑制相比，仅使用RAS（ON）多选择性抑制剂进行广谱、可逆的RAS-GTP抑制可推动这些模型具有持久的抗肿瘤活性，耐药性不常发生，也有可能出现罕见的持久性慢循环细胞
REDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Cancer Discovery. The scientific paper demonstrates that the RAS(ON) multi-selective inhibitor RMC-7977 (a preclinical tool compound representative of the investigational drug candidate RMC-6236) exhibited robust and durable anti-tumor activity in multiple preclinical models of KRAS-mutated NSCLC. The data show this activity was further enhanced in the doublet combination with a RAS(ON) G12C-selective inhibitor RMC-4998 (a preclinical tool compound representative of the investigational drug RMC-6291), in preclinical models of KRAS G12C-mutated NSCLC. These findings are the result of original, collaborative research between scientists at Revolution Medicines and The University of Texas MD Anderson Cancer Center.
加利福尼亚州雷德伍德城，2024年7月11日（GLOBE NEWSWIRE）——为RAS成瘾的癌症患者开发靶向疗法的临床阶段肿瘤公司Revolution Medicines, Inc.（纳斯达克股票代码：RVMD）今天宣布在《癌症发现》上发表了一篇经过同行评审的研究论文。该科学论文表明，RAS（ON）多选择性抑制剂 RMC-7977（代表研究候选药物 RMC-6236 的临床前工具化合物）在多个KRAS突变非小细胞肺癌的临床前模型中表现出强大而持久的抗肿瘤活性。数据显示，在KRAS G12C突变非小细胞肺癌的临床前模型中，与RAS（ON）G12C选择性抑制剂 RMC-4998（代表在研药物 RMC-6291 的临床前工具化合物）的双重组合，这种活性进一步增强。这些发现是Revolution Medicines和德克萨斯大学医学博士安德森癌症中心的科学家进行的原创合作研究的结果。